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The overall objective of cell transplantation is to repopulate postinfarction scar with contractile cells, thus improving systolic
function, and to prevent or to regress the remodeling process. Direct implantation of isolated myoblasts, cardiomyocytes,
and bone-marrow-derived cells has shown prospect for improved cardiac performance in several animal models and patients
suﬀering from heart failure. However, direct implantation of cultured cells can lead to major cell loss by leakage and cell death,
inappropriate integration and proliferation, and cardiac arrhythmia. To resolve these problems an approach using 3-dimensional
tissue-engineered cell constructs has been investigated. Cell engineering technology has enabled scaﬀold-free sheet development
including generation of communication between cell graft and host tissue, creation of organized microvascular network, and
relatively long-term survival after in vivo transplantation.
1. Introduction
Cardiac repair by cell therapy oﬀers hope to improve per-
formance of diseased heart by reconstituting or maintaining
cardiac specific tissue [1]. First studies were performed with
cells such as myoblasts [2], but later the field expanded to
several cell types including bone marrow cells [3], endothe-
lial progenitors [4], mesenchymal stem cells (MSCs) [5], re-
sident cardiac stem cells [6], and embryonic stem cells
[7]. Numerous preclinical studies have shown improved
cardiac function in animal models of heart failure, but the
underlying mechanisms of this improvement have remained
obscure.
Nevertheless, the hypothesis that cardiac function in
heart failure can benefit from cell therapy has gained exten-
sive attention and preliminary clinical trials have been
launched [8–14]. Miyagawa et al., reported their first clinical
trial with combined cell therapy instead of single cell therapy
for a patient based on their finding that combined cell
therapy (both myoblasts and bone marrow mononuclear
cells) has a more synergistic eﬀect on severely damaged
myocardium [15]. In this case recovery of cardiac function
and histological changes were observed. However, they could
not establish if the dramatic functional improvement was
attributable to decreased left ventricle (LV) distension by a
left ventricular assist system (LVAS) or to the cell transplan-
tation due to lack of an appropriate control. The brain natri-
uretic peptide (BNP) levels were significantly lower after cell
transplantation than under LVAS before cell transplantation
[15]. However, for those patients with ischemic cardiomy-
opathy, LVAS implantation alone does not achieve suﬃcient
recovery of myocardial function. After LVAS implantation,
decreased LV distension contributed to the reduced cell di-
ameter and lower BNP [15]. They also detected other changes
such as improved regional diastolic function and vascular
density in the targeted region, in addition to the changes
evoked by LVAS implantation. This indicates that cell trans-
plantation had a positive eﬀect on the distressed ischemic
myocardium. Yet, the mixed results received from the clinical
studies have regained the interests for laboratory work.
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Table 1: Cell transplantation by intramyocardial injection and vascular infusion in clinical studies.
Cell injection to myocardium
Cell type ×106 cells Function Remarks
Myoblast . . . ↑ Arrhythmogenic potential [20]
Myoblast 206 No eﬀect Arrhythmogenic potential [21]
Myoblast 400–800 No eﬀect Arrhythmia [14]
Myoblast 870 . . . Arrhythmogenic potential [22]
Myoblast, BMSC 300, 100 ↑ [15]
Vascular infusion
Cell type ×106 cells Function Remarks
BMSC ∼1.5–9 . . . Restoration of coronary flow reserve [12]
BMSC 39 ↑ [13]
BMSC 68 No eﬀect [11]
BMSC ∼100–300 ↑ Lower mortality [8]
BMSC 200–400 No eﬀect Infarct remodelling [10]
BMSC 56–60 000 ↑ [9]
BMSC: bone marrow stem cell.
2. Cell Delivery by Injection
One of the crucial issues in cell therapy for heart failure has
been the cell delivery route. Injection of the cells has been the
most typical method in clinical feasibility studies (Table 1).
The cells have been injected directly into the myocardium or
into the coronary vasculature. However, several underlying
issues make this a challenging technique to use clinically. The
injected cells can be washed out through channel leakage and
the vascular system, creating a significant loss of grafted cells
[16–18]. Additional loss of the grafted cells is generated by
the disruption of the extracellular matrix and the subsequent
loss of signals that modulate cell survival, diﬀerentiation, and
patterning [19].
In addition, arrhythmogenicity of intramyocardial my-
oblast transplantation has aroused debate. Episodes of
ventricular tachycardia and fibrillation have been noted after
several feasibility studies. Due to small number of patients
in nonrandomized series and the arrhythmogenic nature
of the heart disease itself, direct causality is diﬃcult to
conclude. In an early study of Menasche´ et al., 4 out of
10 patients experienced sustained ventricular tachycardia
[22], and in the study by Smits et al., 4 out of 15 patients
experienced clinically significant arrhythmias in the early
phase [20]. A four-year surveillance of the patients showed
more intracardiac defibrillator (ICD) interventions when
compared to a matched patient population [21]. According
to the preliminary data, all patients in MAGIC trial received
an ICD implant. At one year after the myoblast injections,
no significant diﬀerence was found between the myoblast-
treated group or the control group regarding arrhythmo-
genicity [14]. To overcome this evident problem, several
strategies for preventing cell therapy-associated arrhythmias
have been introduced. Genetic engineering by overexpressing
connexin-43 by the transplanted cells might improve the
cell graft integration to the host [23]. Myocardial dam-
age resulting from multiple needle injections is potentially
a significant cause to ventricular arrhythmias. Avoiding the
injections by using intracoronary delivery might decrease
arrhythmia [24], although cell loss has been described [25].
Still, even more important aspect would be to improve the
method of cell delivery. Various cell types and their deliv-
ery methods into damaged myocardium are compared in
Table 2.
3. Cell Delivery by Injection versus Cell Sheets
Another approach for cell delivery as opposed to injection
involves tissue-engineered constructs. Themain advantage of
this technology over standard cell implantation lies on the
preservation of microcellular communication and matrix,
which is lost upon trypsin treatment in the typical procedure
of cell preparation. Epicardial deposition of cell sheets might
be a solution to prevent significant cell loss and arrhythmia
after cell transplantation [26]. Memon et al., reported that
myoblast sheet implantation improved global cardiac func-
tion to a greater extent than the injection of cell suspension
[27]. Similarly, in a recent study, myoblast cell sheets were
compared to direct injections of myoblast cells in ischemic
heart failure (Patila et al., submitted). Holter monitoring
showed more ventricular premature contractions in the cell
injection group. Furthermore, epicardial electropotential
mapping showed areas of electrical reentry in the injection
sites. RT-PCR showedmore inflammatory markers andmore
inflammatory cells accumulated at the infarct border area in
the injection group, when compared to the cell sheet-treated
animals (Patila et al., submitted).
4. Cell Sheets in Diseased Heart
Current tissue engineering methods allow us to reconstruct
myocardial tissue grafts for clinical applications, though
human fetal and neonatal cardiomyocytes are diﬃcult to
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Table 2: Cell types and delivery methods in cardiac functional outcome.
Cell injection to myocardium
Model Cell type ×106 cells Function Remarks
Mouse BMSC 0.0175–0.1 ↑ Regeneration [1]
Rat BMSC 10 ↑ Arrhythmogenicity [24]
Rat BMSC 20 ↑ [23]
Rat CM 0.2 ↑ Regeneration [6]
Rat CM 5 . . . Cell washout [16]
Rat Myoblast 1 ↑ Improved exercise capacity [28]
Rat Myoblast 2.3 ↑ [29]
Rat Myoblast 10 ↑ Arrhythmogenicity [23]
Rabbit FB ↑ diastolic, ↓systolic performance [30]
Rabbit Myoblast ↑ [30]
Sheep Myoblast . . . ↑ [31]
Swine BMSC 100 . . . Cell washout [17]
Swine BMSC 100 . . . High cell homing [25]
Vascular infusion
Model Cell type ×106 cells Function Remarks
Mouse BMSC 20 . . . Regeneration [3]
Rat BMSC 10 ↑ [24]
Swine BMSC 100 . . . Cell washout [25]
Cell sheets
Model Cell type Nr of sheets Function Remarks
Hamster Myoblast 2 layers ↑ Higher life expectancy [32]
Rat AdMSC Monolayer ↑ Paracrine
pathways—angiogenesis
[33]
Rat AdMSC Monolayer ↑ [34]
Rat CM, SC Monolayer ↑ Cell survival, proliferation,
diﬀerentiation
[35]
Rat CM, EC “Monolayer” ↑ Higher vessel density [36]
Rat CM 2 monolayers ↑ Integration of graft and
myocardium
[37]
Rat CM Bilayer Functional integration [26]
Rat CM 3 monolayers . . .
Integration of graft and
myocardium
[38]
Rat CM 3 monolayers . . . Thick grafts, multiple surgeries [39]
Rat FB, EC 3 monolayers ↑ Less fibrosis [40]
Rat Myoblast 1–5 monolayers ↑ Dose-response [41]
Rat Myoblast 2 monolayers ↑ Less fibrosis, remodeling [27]
Rat Myoblast 2 layers ↑ Less fibrosis, higher vessel
density
[42]
Rat Myoblast 2 × 5 layers ↑ Higher vessel density [43]
Rat Myoblast 2 × 5 layers ↑ Paracrine pathways—
angiogenesis
[44]
Swine Myoblast 2–10 layers ↑ [45]
AdMSC: adipose tissue-derived mesenchymal stem cell, BMSC: bone marrow stem cell, CM: cardiomyocyte, EC: endothelial cell, FB: fibroblast, SC: stromal
cell.
obtain. Therefore, several classes of stem cells are being
investigated as a potential cell source. Despite their attractive
potential to diﬀerentiate into various cell types, several issues
remain, including diﬃculties in obtaining and amplifying the
cells and the lack of understanding of the mechanisms for
diﬀerentiation and proliferation. Consequently, the clinical
cell sheet transplantation has mainly focused on utilization
of myoblasts.
Memon et al., [27] reported the use of skeletal myoblast
sheets in a rat myocardial infarction model. Preclinical data
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have shown that autologous skeletal myoblasts are capable
not only of fusion and diﬀerentiation into striated muscle
cells within damaged myocardium [31] but also of aug-
menting systolic and diastolic performance in animal models
of acute myocardial infarction and heart failure [28–30, 46].
Inhibition of apoptosis in myoblast sheets by expression of
antiapoptotic bcl2 was shown to enhance the eﬃcacy of sheet
transplantation therapy in acute myocardial infarction [43].
Moreover, Siltanen et al. demonstrated that prevention of
graft apoptosis by bcl2 improved myoblast sheet transplan-
tation therapy also in chronic myocardial infarction model
[44].
Dilated cardiomyopathy (DCM) is characterized by glob-
al myocardial remodeling, which mainly consists of myocar-
dial fibrosis associated with changes in the cytoskeletal and
sarcolemmal proteins in cardiomyocytes, leading to a reduc-
tion in the number and function of these cells [47]. Con-
sequently, cardiac remodeling chronically progresses with
ventricular dilation and thinning, leading to progressive
congestive heart failure. Kondoh et al. used human hered-
itary DCM representative model of TO-2 hamster strain
[32]. In this hamster strain, the number of cardiomyocytes
decreases progressively because of apoptosis after birth, and
cardiac remodeling, which mainly consists of myocardial
fibrosis, occurs with ventricular dilation and thinning, lead-
ing to progressive congestive heart failure. Transplantation of
myoblast sheet grafts showed reorganization of the cytoskele-
tal proteins, reduction of myocardial fibrosis, and prevention
of dilation of the left ventricle, leading to prolonged life
expectancy and a longer preservation of cardiac performance
in the impaired heart.
Hoashi et al., [42] showed that myoblast sheet trans-
plantation improved right ventricular diastolic dysfunction.
Briefly, animals underwent pulmonary artery banding thus
created chronic pressure overload resulting in right ventric-
ular failure. Chronic pressure overload is one of the major
risk factors of right ventricular dysfunction. In this situation
the right ventricle is hypertrophied and systolic function
is initially preserved, whereas diastolic function gradually
deteriorates. Prolonged exposure to excessive pressure over-
load results in irreversible right ventricular failure. Thus they
successfully demonstrated improvement in diastolic dys-
function and suppressed ventricular fibrosis with increased
capillary density in a ratmodel of a pressure-overloaded right
ventricle by implanting myoblast sheets.
Preclinical studies in impaired porcine heart using single
monolayer skeletal muscle cell sheet demonstrated improved
cardiac performance accompanied with increased myocar-
dial perfusion and viable myocardial tissue [45].
Further, Miyahara et al., used mesenchymal stem cells
(MSCs) derived from adipose tissue in a rat myocardial
infarctionmodel [33].MSC sheets incorporated into the host
myocardium and improved cardiac function and increased
survival. Similarly, Okura et al., showed that transplanted
sheets of adipose tissue-derived MSCs diﬀerentiated into
cardiomyoblast-like cells and resulted in recovery of cardiac
function and improved survival rate of rat with infarcted
heart [34].
5. Development of Complex Sheet Structures
Diﬃculties still exist in the outcome of cell therapy, as it
is challenging to control the cell growth and localization
of the grafted cells and to deliver a cell sheet patch that
significantly aids the function of the damaged myocardium.
To overcome these problems research has begun on fabri-
cating three-dimensional cardiac grafts composed of mul-
tilayered cell sheets. Several methods have been studied
with reconstructed tissues based on biodegradable scaﬀolds,
such as poly(lactic-co-glycolic acid) and gelatin or extracel-
lular matrix components [48, 49].
5.1. Fabrication of Scaﬀold-Free Cell Sheets. In native car-
diac tissue the cell density is considerably high, cells
being tightly interconnected with gap junctions facilitating
electrical communication. The use of scaﬀolds can lead
to abnormal tissue development, electrical communication
caused by insuﬃcient cell-to-cell connections, inflammatory
responses, and fibrous tissue formation. Alternatively, fab-
rication of scaﬀold-free cell sheets requires means of cell
detachment from the culture surface that will preserve cell
morphology, orientation within the scaﬀold, and adhesion
to surrounding cells and the extracellular matrix. One
way to achieve such detachment is to covalently employ
a temperature-responsive polymer on cell culture surface.
Poly(N-isopropylacrylamide) (PIPAAm) is a hydrophobic
polymer at temperatures above 32◦C which—after grafting
to cell culture dishes—allows cell adhesion and proliferation
[50]. At temperatures below 32◦C, PIPAAm grafted surfaces
change their properties and become hydrophilic to allow cell
detachment as intact sheets which harbor the ECM on the
basal surface [51]. These sheets retain their cell-to-cell as
well as cell-to-ECM adhesions [51], while cell viability is not
compromised [50]. Further, PIPAAm-grafted surfaces can be
used to engineermonolayer [52] as well as three-dimensional
sheet structures comprised of several cell layers [53].
Stevens et al., and Itabashi et al., described other methods
for creating scaﬀold-free sheets. Stevens et al., created embry-
onic stem cell-derived cardiomyocyte sheets utilizing Teflon-
coated low-attachment tissue culture dishes combined with
rotating orbital shaker [54]. The diameter of these sheets was
dependent on cell number, and the thickness was approxi-
mately 300–600µm. These sheets, however, were subject to
necrosis due to limited oxygen supply. The same method was
then used to create prevascularized sheets composed of car-
diomyocytes, endothelial cells, and fibroblasts. These sheets
eﬀectively integrated with the coronary circulation after
implantation and evaded necrosis. Furthermore, Itabashi
et al., fabricated cardiomyocyte sheets using polymerized
fibrin-coated culture dishes [55]. This method is based on
the proteolytic activity of the cardiomyocytes that degrades
the underlying fibrin coating and allows harvesting of intact
sheets mechanically using a cell scraper.
5.2. Cellular Communication in Cell Sheets. In addition to
cell-to-cell communication, the layers need to establish a
connection with each other and with the host tissue. Using
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a multielectrode extracellular recording system, Haraguchi
et al., demonstrated that the electrical coupling between 2
sheets starts approximately 34 minutes after initial layering
and is completed by about 46 minutes. They also showed
small molecule exchange through gap junctions and presence
of connexin-43 within 30 minutes of layering [56].
When Shimizu et al., implanted a 4-layered neonatal rat
cardiomyocyte sheet into the subcutaneous space of nude
rats, synchronous beating [57] and survival up to 1 year [58]
were observed. The implanted graft showed characteristic
structures of heart tissue, including elongated cardiomy-
ocytes, well-diﬀerentiated sarcomeres, and gap junctions.
Additionally, conduction velocity, contractile force, and size
of implanted grafts increased in proportion to the host’s
growth [58]. Hata et al., further showed synchronous con-
traction with defined direction of neonatal rat cardiomyocyte
sheets on decellularised porcine small-intestinal submucosa
[59].
Miyagawa and colleagues showed that neonatal cardiom-
yocyte sheets fabricated on temperature-responsive culture
dishes attached to the infarcted myocardium and led to an
improvement in cardiac performance and improved vascular
density [37]. The implanted sheets communicated with the
host myocardium as indicated by the presence of connexin-
43 and changes in the QRS wave and action potential
amplitude.
Another study demonstrated a similar electrical integra-
tion between a neonatal myocyte sheet and the host myo-
cardium without serious arrhythmia [26]. Furthermore, his-
tological analyses in infarcted rat hearts with a transplanted
3D tissue graft showed bridging of the cardiomyocytes with
functional gap junctions and intercalated disks [38].
5.3. Recreation of Microvessels and Cell Sheet Survival. Heart
is a metabolically active organ that requires virtually constant
oxygen supply in order to function in a normal fashion.
The major limitation of the multilayered cell grafts is insuf-
ficient circulation causing hypoxia, nutrient insuﬃciency,
and accumulation of waste products. Cells in living tissues
receive oxygen supply through a capillary network, whereas
the cultured cell aggregates in vitro rely on diﬀusion. In order
to reconstruct thicker and metabolically active tissue grafts
suﬃcient blood supply network has to be created.
One strategy could be to generate capillary-like networks
in vitro in tissue-engineered constructs before transplan-
tation. Levenberg et al., demonstrated the induction of
endothelial vessel networks in engineered skeletal muscle
tissue constructs using a 3D culture system consisting of
myoblasts, embryonic fibroblasts, and endothelial cells co-
seeded on porous, biodegradable polymer scaﬀolds [60].
Similar spontaneous 3D prevascular network formation has
been shown also in in vitro bone coculture model with
human MSCs, human umbilical vein endothelial cells
(HUVECs) [61, 62], and in human endothelialized recon-
structed skin (ERS), including keratinocytes, fibroblasts, and
endothelial cells in a collagen sponge [63]. As the recon-
structed skin was transplanted to a nude mouse, Tremblay
et al., concluded that the early vascularization observed
in the ERS was most likely the result of inosculation of
the capillary-like structures with the host’s capillaries, rather
than neovascularisation, which is a slower process.
Sasagawa et al., developed a novel cell sheet stacking
manipulation technique to create multilayered cell sheets
from human skeletal muscle myoblasts [64]. They placed
a hydrogel-coated plunger onto a confluently cultured cell
layer in a temperature-responsive culture dish. To harvest
the cell layer the temperature was decreased to 20◦C after
which the plunger with the cell layer was transferred onto
another confluent myoblast monolayer in another dish and
incubated at 37◦C to promote the cell layer adhesion. After
30–50 minutes in 20◦C the plunger was lifted up with a
double-layer myoblast sheet. They were able to reach a 5-
layered construct with this procedure, which did no harm to
the cells confirmed by cell viability assay. To further develop a
viable cell dense tissue construct Sasagawa et al., sandwiched
HUVECs into the 5-layer myoblast sheet construct. Four
days after culture, the HUVECs had started to develop into
capillary-like structures. One week after the constructs were
engrafted on the dorsal subcutaneous tissue of nude rat,
newly formedmicrovessels connected to the host vessels were
found.
A single myoblast layer is about 45 µm thick [57]. Accord-
ingly, most previous studies used multilayer constructs up to
about 250 µm thick. In order to progress the human cell sheet
applications the greater thickness of the construct would be
of great advantage. Sekiya et al., investigated the relationship
between the number of transplanted cell layers and cardiac
function. They found a significant improvement of cardiac
function, induction of angiogenesis, more elastic fibers, and
less fibrosis with implantation of 3- and 5- layered myoblast
sheets compared to single layer [41].
Shimizu et al., showed that the 1-, 2-, and 3-layer con-
structs transplanted into the dorsal subcutaneous tissue
of nude rats thoroughly survived without necrosis [39].
However, parts of the 4- and 5-layer constructs showed
disordered vasculature and connective tissue, indicative of
necrosis. Subsequently, transplantation of two triple-layer
grafts at 1-day intervals permitted whole tissue survival
with a well-organized microvascular network, whereas 2-
and 3-day transplantation intervals had poor outcome.
Shimizu et al., further developed the polysurgical method
by transplanting up to 10 triple-layer cell sheet grafts at 1-
or 2-day intervals. Interestingly, at one week after the final
transplantation about 0.9mm thick cell-dense myocardium
graft revealed vigorousmyocardium-like pulsation with well-
organized microvessels throughout the graft. This poly-
surgical method would encounter diﬃculties in clinical
replacement therapy as each procedure has a relatively high
risk of complications. To overcome this obstacle, Shimizu et
al., developed an ectopic construct repeatedly transplanting
the layered cell sheets over an exposed superficial caudal
epigastric, and femoral artery and vein of a nude rat. After
2 weeks the pulsating graft was resected together with the
femoral artery and vein and further connected to carotid
artery and the jugular vein in a new host. The grafts survived
and maintained their characteristic beating 2 weeks after
the procedure.
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5.4. Angiogenesis in Cell Sheets. One way to enhance the cell
sheet graft survival is to promote angiogenesis. Enhanced
angiogenesis and functional improvement were achieved by
using cocultured cell sheets with fibroblasts and endothelial
progenitor cells [40]. Another study showed an accelerated
secretion of angiogenic factors in vitro and increased blood
perfusion in vivo by using a coculture of fibroblasts and
human smooth muscle cells [65]. In addition, Sekine et al.,
showed that a coculture of cardiomyocytes and endothelial
cells in a cell sheet enhanced vascularization and that the
implanted sheet improved cardiac performance compared
with a cardiomyocyte-only sheet [36].
Stimulation of angiogenesis has also been shown in single
cell-type cell sheets. Miyagawa et al., demonstrated that
human HGF gene transfection enhanced the cellular car-
diomyoplasty likely by stimulating angiogenesis, restoring
the impaired extracellular matrix, and promoting the inte-
gration of the dissociated grafted myocytes [66]. Zakharova
et al., fabricated sheets from cardiac progenitor cells and
showed that these sheets improved cardiac function, sup-
pressed wall thinning, and increased vascular density [35].
To understand the molecular mechanisms of cell sheet
angiogenesis Sekiya et al., studied both in vitro and in vivo
models and demonstrated that cardiac cell sheets express
VEGF, Cox-2, and Tie-2 and exhibit endothelial cell organ-
isation and microvessel formation [67]. Kitabayashi et al.,
showed that myoblast sheets express proangiogenic VEGF
and placental growth factor and that implantation of these
sheets induces angiogenesis in vivo. Expression of these
proangiogenic genes was further induced by preventing graft
apoptosis with antiapoptotic gene therapy [43]. Moreover,
Siltanen et al., showed that the proangiogenic eﬀect of
myoblast sheets is mediated via the Flt1/Flk-1 pathway [44].
Memon et al., reported expression of SDF-1, HGF, and VEGF
in the myocardium after myoblast sheet transplantation [27].
Finally, expression of human HGF in myoblast sheets further
enhanced the proangiogenic potential of myoblast sheet
therapy [68]. In this study, HGF-expressing sheet therapy
increased vascular density in the infarct and border area, as
well as in the noninfarcted myocardium.
6. Conclusion
Diﬃculties in reproducibility in cell injection therapy, in-
cluding low survival and function of the cells, have led to
search for more robust methods. Engineering of 3D cell
constructs has currently been under extensive investiga-
tion. Preassembled cell constructs might provide eﬀective
tools for the future cell therapy research. Establishment of
programmable materials used in the cell engineering tech-
nology has enabled the creation of scaﬀold-free cell sheets in
a rather simple and inexpensive method. The main aspects
of cell sheet construction that must be met for successful
regenerative therapy are dynamic, electrical, and histological
integration. Increased cell-to-cell communication and sur-
vival in cell sheets warrant further attention. The reviewed
studies demonstrate the existing potential to produce
viable, functional myocardial tissue implantable constructs
well beyond the current diﬀusion-limited thickness re-
gime.
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